Atlanta, GA Clinical Trials Report — June 2026

For Atlanta residents exploring opportunities to contribute to medical research, June 2026 presents a dynamic landscape of clinical trials. With 1,403 trials currently recruiting across 543 research facilities in the city, there are numerous avenues for participation. This month, particular attention should be paid to trials nearing their enrollment deadlines, as well as exciting new studies from major sponsors.

Act Quickly: Trials Nearing Conclusion

Individuals interested in participating in clinical research should note that 94 trials in Atlanta are scheduled to close within the next 90 days. This urgency applies to patients with specific conditions and healthy volunteers alike. Of these closing trials, 8 are still actively seeking healthy volunteers, offering a chance to contribute to medical advancements before their enrollment windows close.

Patients managing specific health conditions also face impending deadlines to join research. Conditions with trials closing soon include:

• Sickle cell disease (3 trials)
• Advanced breast cancer (3 trials)
• Major depressive disorder (3 trials)
• Heart failure (3 trials)
• Hematologic malignancy (2 trials)
• Acute myeloid leukemia (2 trials)
• Metastatic breast cancer (2 trials)
• Aortic valve insufficiency (2 trials)
• Duchenne muscular dystrophy (2 trials)
• Breast cancer (2 trials)

New Research Opportunities in Atlanta

This month, Atlanta saw the opening of 25 new clinical trials, a slight increase from the 24 trials that launched in May 2026. This consistent activity highlights Atlanta's role as a growing hub for medical innovation.

New trials this month are exploring a range of conditions, with the most frequent being overweight (2 trials) and obesity (2 trials). Other conditions include aneuploidy, autism spectrum disorder, bone density, cataplexy, type 2 diabetes mellitus, high-grade B-cell lymphoma (HGBCL), diffuse large B cell lymphoma (DLBCL), and Down syndrome (Trisomy 21). Drug trials account for the largest share of new studies, with 14 new drug trials, followed by 4 behavioral studies and 2 device trials.

Notable sponsors leading new research efforts include Emory University, Morehouse School of Medicine, Kallyope Inc., Eli Lilly and Company, Gasherbrum Bio, Inc. (a wholly owned subsidiary of Structure Therapeutics), Harmony Biosciences Management, Inc., and Hoffmann-La Roche. Industry sponsors are driving 14 of the new trials, while academic institutions like Emory University are sponsoring 5.

Spotlight on Key New Trials

June brings several high-profile new trials to Atlanta, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Kallyope Inc. is initiating a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Also from Kallyope Inc., NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," is a Phase 3 study seeking 1,000 participants to evaluate the long-term safety and tolerability of intermittent use of elismetrep.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This Phase 3, randomized, double-blind, placebo-controlled study will evaluate the long-term efficacy, safety, and tolerability of aleniglipron in 1,100 participants over 76 weeks.
• Revolution Medicines, Inc. is leading NCT07621718, "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )." This Phase 3 study aims for 670 participants to evaluate the efficacy of an investigational RAS(ON) inhibitor in combination with chemotherapy.
• Emory University is sponsoring NCT07651631, "Rapid Evacuation and Access of Cerebral Hemorrhage Registry." This observational study aims to quantify the real-world effect of minimally invasive surgery in patients with acute spontaneous supratentorial intracerebral hemorrhage, involving 2,500 participants.
• BillionToOne Inc. is leading NCT07643896, "The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study." This observational study seeks 1,000 participants to compare a novel non-invasive circulating fetal cell (CFC) assay to prenatal invasive diagnostic testing or postnatal genetic and clinical diagnoses.

Atlanta's Leading Research Hubs

Atlanta is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Emory University (197 trials)
• Emory University Hospital/Winship Cancer Institute (127 trials)
• Emory University Hospital Midtown (120 trials)
• Emory University Hospital (90 trials)
• Emory Saint Joseph's Hospital (82 trials)
• Children's Healthcare of Atlanta (50 trials)
• Northside Hospital (47 trials)
• Emory University School of Medicine (47 trials)
• Grady Health System (47 trials)
• Research Site (43 trials)
• Children's Healthcare of Atlanta - Arthur M Blank Hospital (36 trials)
• Winship Cancer Institute, Emory University (30 trials)

The Emory University system, including its various hospitals and institutes, clearly leads in the volume of trials, indicating its significant role in Atlanta's research landscape. Children's Healthcare of Atlanta also stands out as a major site for pediatric research.

Expanding Your Search: Nearby Georgia Cities

While Atlanta offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Georgia. Cities with active trials include Decatur (5 trials), Woodstock (5 trials), Marietta (3 trials), Roswell (2 trials), Lawrenceville (2 trials), Norcross (2 trials), Stockbridge (2 trials), and Union City (2 trials).

Who Can Participate? Diverse Opportunities

Participation in clinical trials is open to a diverse range of individuals. Of the 25 new trials launched this month, 23 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 4 new trials include children, 3 are female-only, and 1 is male-only.

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 3 of the 25 new trials launched this month are actively seeking healthy volunteers. Across Atlanta, a total of 117 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

As we move through June, Atlanta's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.